UiPath (NYSE:PATH) Stock Price Down 4.6% on Insider Selling

Key Points

• UiPath's stock price fell 4.6% following insider selling, with about 37.5 million shares traded, significantly exceeding the average daily volume.
• Notable insider sales included CEO Daniel Dines selling 122,734 shares and CAO Hitesh Ramani selling 10,000 shares, reflecting significant decreases in their positions.
• Analysts have mixed ratings on UiPath, with a consensus rating of "Hold" and a price target averaging $13.21, while some firms have recently downgraded their price objectives.

UiPath, Inc. (NYSE:PATH - Get Free Report)'s share price dropped 4.6% on Thursday following insider selling activity. The company traded as low as $15.80 and last traded at $15.93. Approximately 37,526,140 shares changed hands during trading, an increase of 164% from the average daily volume of 14,193,625 shares. The stock had previously closed at $16.69.

Specifically, CAO Hitesh Ramani sold 10,000 shares of the firm's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $16.68, for a total value of $166,800.00. Following the transaction, the chief accounting officer owned 232,776 shares of the company's stock, valued at approximately $3,882,703.68. This trade represents a 4.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Dines sold 122,734 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $16.92, for a total transaction of $2,076,659.28. Following the completion of the sale, the chief executive officer owned 122,734 shares of the company's stock, valued at approximately $2,076,659.28. This trade represents a 50.00% decrease in their position. The disclosure for this sale can be found here. In other UiPath news, insider Brad Brubaker sold 27,580 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $16.68, for a total value of $460,034.40. Following the completion of the sale, the insider owned 662,939 shares in the company, valued at approximately $11,057,822.52. This trade represents a 3.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Analyst Upgrades and Downgrades

Several research firms have commented on PATH. Weiss Ratings reiterated a "sell (d)" rating on shares of UiPath in a research note on Wednesday, October 8th. Needham & Company LLC reiterated a "hold" rating on shares of UiPath in a research note on Friday, September 5th. Truist Financial decreased their price objective on shares of UiPath from $13.00 to $12.00 and set a "hold" rating for the company in a research note on Friday, September 5th. Zacks Research upgraded shares of UiPath from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 8th. Finally, Canaccord Genuity Group decreased their price target on shares of UiPath from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $13.21.

UiPath Price Performance

The firm's 50 day moving average is $12.32 and its 200 day moving average is $12.14. The firm has a market cap of $8.46 billion, a P/E ratio of 531.00, a price-to-earnings-growth ratio of 6.10 and a beta of 1.07.

UiPath (NYSE:PATH - Get Free Report) last issued its earnings results on Thursday, September 4th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The firm had revenue of $361.73 million for the quarter, compared to the consensus estimate of $347.36 million. UiPath had a net margin of 1.35% and a return on equity of 1.28%. The business's revenue was up 14.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.04 earnings per share. UiPath has set its FY 2026 guidance at EPS. Q3 2026 guidance at EPS. As a group, analysts expect that UiPath, Inc. will post -0.17 EPS for the current year.

Hedge Funds Weigh In On UiPath

Several institutional investors have recently bought and sold shares of PATH. Twin Peaks Wealth Advisors LLC bought a new stake in shares of UiPath in the 2nd quarter worth about $28,000. AdvisorNet Financial Inc raised its stake in shares of UiPath by 320.4% during the 2nd quarter. AdvisorNet Financial Inc now owns 2,476 shares of the company's stock worth $32,000 after acquiring an additional 1,887 shares in the last quarter. CX Institutional purchased a new stake in UiPath during the 1st quarter worth approximately $36,000. GAMMA Investing LLC grew its position in UiPath by 48.0% during the 2nd quarter. GAMMA Investing LLC now owns 2,989 shares of the company's stock worth $38,000 after purchasing an additional 969 shares during the last quarter. Finally, IFP Advisors Inc grew its position in UiPath by 508.0% during the 2nd quarter. IFP Advisors Inc now owns 3,283 shares of the company's stock worth $42,000 after purchasing an additional 2,743 shares during the last quarter. 62.50% of the stock is owned by hedge funds and other institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.